IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 4, Issue 1 (2023)
J Clinic Care Skill 2023, 4(1): 1-7 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi M, Sayadi M, Hemmati A, Moradi Ardakani F, Sattari F, Javidi ALesaadi S, et al . The Reasons of Avoiding Vaccination Against COVID-19 in Eligible Population of Fars Province, Iran. J Clinic Care Skill 2023; 4 (1) :1-7
URL: http://jccs.yums.ac.ir/article-1-161-en.html
URL: http://jccs.yums.ac.ir/article-1-161-en.html
M.R. Karimi1 
, M. Sayadi2 , A. Hemmati1 , F. Moradi Ardakani3 , F. Sattari1 , SH. Javidi ALesaadi1 , B. Lashgarara1 , M. Saeedfiroozabadi * 4
, M. Sayadi2 , A. Hemmati1 , F. Moradi Ardakani3 , F. Sattari1 , SH. Javidi ALesaadi1 , B. Lashgarara1 , M. Saeedfiroozabadi * 4
1- Vice Chancellor of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2- Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4- Vice Chancellor of Health, Shiraz University of Medical Sciences, Shiraz, Iran , Maryamsaeedfiroozabadi56@gmail.com
2- Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4- Vice Chancellor of Health, Shiraz University of Medical Sciences, Shiraz, Iran , Maryamsaeedfiroozabadi56@gmail.com
Abstract: (850 Views)
Aims: The new coronavirus disease (COVID-19), as a second epidemic of the 21st century, causes severe acute respiratory syndrome in patients. This study was designed to determine the causes of not vaccinating against COVID-19 in the eligible population of Fars province.
Instrument & Methods: This cross-sectional study was carried out in December 2021 to March 2022 on unvaccinated people of Fars province, Iran. The data of 12889 individuals were added to the study. The data collection tool was a researcher-made checklist with closed-ended questions that were completed through a telephone interview. Data were analyzed using SPSS 22 software through descriptive statistics and a Chi-square test.
Findings: The largest age group was 25 to 35 years old (19.8%). The percentage of unvaccinated females was significantly higher than males (p<0.001). Homemakers and college and school students were the occupational groups with the highest frequency of not receiving the vaccine. The considerable reasons for not being vaccinated are the side effects anxiety, and lack of belief in the vaccine conspiracy.
Conclusion: The women of reproductive age and college and school students are the most frequent unvaccinated groups. Having an underlying disease and the lack of follow-up by the healthcare staff are the most frequent reason for not being vaccinated.
Instrument & Methods: This cross-sectional study was carried out in December 2021 to March 2022 on unvaccinated people of Fars province, Iran. The data of 12889 individuals were added to the study. The data collection tool was a researcher-made checklist with closed-ended questions that were completed through a telephone interview. Data were analyzed using SPSS 22 software through descriptive statistics and a Chi-square test.
Findings: The largest age group was 25 to 35 years old (19.8%). The percentage of unvaccinated females was significantly higher than males (p<0.001). Homemakers and college and school students were the occupational groups with the highest frequency of not receiving the vaccine. The considerable reasons for not being vaccinated are the side effects anxiety, and lack of belief in the vaccine conspiracy.
Conclusion: The women of reproductive age and college and school students are the most frequent unvaccinated groups. Having an underlying disease and the lack of follow-up by the healthcare staff are the most frequent reason for not being vaccinated.
Article Type: Original Research |
Subject:
Special
Received: 2022/11/13 | Accepted: 2023/01/18 | Published: 2023/03/6
Received: 2022/11/13 | Accepted: 2023/01/18 | Published: 2023/03/6
References
1. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36. [DOI:10.1080/22221751.2020.1719902]
2. Bordi L, Nicastri E, Scorzolini L, Di Caro A, Capobianchi MR, Castilletti C, et al. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill. 2020;25(8):2000170. [DOI:10.2807/1560-7917.ES.2020.25.8.2000170]
3. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;371. [DOI:10.1136/bmj.m4471]
4. Meo S, Bukhari I, Akram J, Meo A, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9. [link]
5. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-4. [DOI:10.1016/S0140-6736(20)32623-4]
6. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372. [DOI:10.1136/bmj.n699]
7. Mallapaty S, Callaway E. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine. Nature. 2021;592(7852):15-7. [DOI:10.1038/d41586-021-00785-7]
8. Livingston EH, Malani PN, Creech CB. The Johnson and Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575. [DOI:10.1001/jama.2021.2927]
9. Mahase E. Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots. BMJ. 2021;373. [DOI:10.1136/bmj.n970]
10. De Matos A, Cardoso GP, Neto M. Sputnik v: Is the Russian vaccine safe. J Clin Epidemiol Toxicol. 2021;2(3):1-2. [link]
11. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. J Travel Med. 2021;28(4):taab051. [DOI:10.1093/jtm/taab051]
12. Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. [DOI:10.1136/bmj.n296]
13. Griffin S. Covid-19: China's CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds. Bmj. 2021;374. [DOI:10.1136/bmj.n1755]
14. Baraniuk C. What do we know about China's covid-19 vaccines?. BMJ. 2021;373. [DOI:10.1136/bmj.n912]
15. Basiri N, Koushki M. Study of vaccine production abroad and scientific and research challenges of COVID-19 vaccine production in Iran. Annals Romanian Society Cell Biol. 2021;25(4):17249-56. [link]
16. Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first?. Sci Adv. 2021;7(6):eabf1374. [DOI:10.1126/sciadv.abf1374]
17. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-6. [DOI:10.1126/science.abb8923]
18. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. The role of trust in the likelihood of receiving a COVID-19 vaccine: Results from a national survey. Prev Med. 2021;153:106727. [DOI:10.1016/j.ypmed.2021.106727]
19. Keshmiri S, Darabi AH, Tahmasebi R, Vahdat K, Noroozi A. Factors influencing COVID-19 vaccine acceptance based on the behavioral change wheel model in Bushehr province in 2021: A web-based study. Hayat. 2021;27(2):190-205. [Persian] [link]
20. French J, Deshpande S, Evans W, Obregon R. Key guidelines in developing a pre-emptive COVID-19 vaccination uptake promotion strategy. Int J Environ Res a public health. 2020;17(16):5893. [DOI:10.3390/ijerph17165893]
21. Latkin CA, Dayton L, Yi G, Konstantopoulos A, Boodram B. Trust in a COVID-19 vaccine in the US: A social-ecological perspective. Soc Sci Med. 2021;270:113684. [DOI:10.1016/j.socscimed.2021.113684]
22. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines. 2021;9(2): 160. [DOI:10.3390/vaccines9020160]
23. Shekhar R, Sheikh AB, Upadhyay S, Singh M, Kottewar S, Mir H, et al. COVID-19 vaccine acceptance among health care workers in the United States. Vaccines. 2021;9(2):119. [DOI:10.3390/vaccines9020119]
24. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors affecting COVID-19 vaccine acceptance: An international survey among low-and middle-income countries. Vaccines. 2021;9(5):515. [DOI:10.3390/vaccines9050515]
25. Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, et al. Women's views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: A multi-methods study in the UK. BMC Pregnancy Childbirth. 2022;22(1):33. [DOI:10.1186/s12884-021-04321-3]
26. Biswas N, Mustapha T, Khubchandani J, Price JH. The nature and extent of COVID-19 vaccination hesitancy in healthcare workers. J Community Health. 2021;46(6):1244-51. [DOI:10.1007/s10900-021-00984-3]
27. Yoda T, Katsuyama H. Willingness to receive COVID-19 vaccination in Japan. Vaccines. 2021;9(1):48. [DOI:10.3390/vaccines9010048]
28. Vardanjani HM, Imanieh MH, Hassani A-H, Bagheri-Lankarani K. Public trust in healthcare system and its correlates during the COVID-19 Epidemic in Iran. Researchsquare. 2020;1. [DOI:10.21203/rs.3.rs-106242/v1]
29. Hatami S, Hatami N. The role of trust in receiving or not receiving COVID-19 vaccine. J Marine Med. 2021;3(4):20-7. [Persian] [link]
30. Bagheri Sheykhangafshe F. COVID-19 vaccination: Challenges and opportunities. J Rafsanjan Univ Med Sci. 2022;20(11):1289-94. [Persian] [DOI:10.52547/jrums.20.11.1289]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |